The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Alpha-1 Lung Disease-Global Market Insights and Sales Trends 2025
Synopsis
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha-1 Lung Disease market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Alpha-1 Lung Disease in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Pharmacies and Others, are propelling Alpha-1 Lung Disease market. Augmentation Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cystic Fibrosis(CF) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alpha-1 Lung Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alpha-1 Lung Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alpha-1 Lung Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alpha-1 Lung Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alpha-1 Lung Disease covered in this report include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.
The global Alpha-1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Global Alpha-1 Lung Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alpha-1 Lung Disease market, Segment by Type:
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Global Alpha-1 Lung Disease market, by Application
Hospitals
Specialty Clinics
Pharmacies
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Alpha-1 Lung Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha-1 Lung Disease market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Alpha-1 Lung Disease in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Pharmacies and Others, are propelling Alpha-1 Lung Disease market. Augmentation Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cystic Fibrosis(CF) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alpha-1 Lung Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alpha-1 Lung Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alpha-1 Lung Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alpha-1 Lung Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alpha-1 Lung Disease covered in this report include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.
The global Alpha-1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Global Alpha-1 Lung Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alpha-1 Lung Disease market, Segment by Type:
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Global Alpha-1 Lung Disease market, by Application
Hospitals
Specialty Clinics
Pharmacies
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Alpha-1 Lung Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Alpha-1 Lung Disease
1.1 Alpha-1 Lung Disease Market Overview
1.1.1 Alpha-1 Lung Disease Product Scope
1.1.2 Alpha-1 Lung Disease Market Status and Outlook
1.2 Global Alpha-1 Lung Disease Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Alpha-1 Lung Disease Market Size by Region (2018-2029)
1.4 Global Alpha-1 Lung Disease Historic Market Size by Region (2018-2023)
1.5 Global Alpha-1 Lung Disease Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Alpha-1 Lung Disease Market Size (2018-2029)
1.6.1 North America Alpha-1 Lung Disease Market Size (2018-2029)
1.6.2 Europe Alpha-1 Lung Disease Market Size (2018-2029)
1.6.3 Asia-Pacific Alpha-1 Lung Disease Market Size (2018-2029)
1.6.4 Latin America Alpha-1 Lung Disease Market Size (2018-2029)
1.6.5 Middle East & Africa Alpha-1 Lung Disease Market Size (2018-2029)
2 Alpha-1 Lung Disease Market by Type
2.1 Introduction
2.1.1 Augmentation Therapy
2.1.2 Cystic Fibrosis(CF)
2.1.3 Non-CF Bronchiectasis(NCFB)
2.1.4 Other
2.2 Global Alpha-1 Lung Disease Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Alpha-1 Lung Disease Historic Market Size by Type (2018-2023)
2.2.2 Global Alpha-1 Lung Disease Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Alpha-1 Lung Disease Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Alpha-1 Lung Disease Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Alpha-1 Lung Disease Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Alpha-1 Lung Disease Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Alpha-1 Lung Disease Revenue Breakdown by Type (2018-2029)
3 Alpha-1 Lung Disease Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Specialty Clinics
3.1.3 Pharmacies
3.1.4 Others
3.2 Global Alpha-1 Lung Disease Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Alpha-1 Lung Disease Historic Market Size by Application (2018-2023)
3.2.2 Global Alpha-1 Lung Disease Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Alpha-1 Lung Disease Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Alpha-1 Lung Disease Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Alpha-1 Lung Disease Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Alpha-1 Lung Disease Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Alpha-1 Lung Disease Revenue Breakdown by Application (2018-2029)
4 Alpha-1 Lung Disease Competition Analysis by Players
4.1 Global Alpha-1 Lung Disease Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alpha-1 Lung Disease as of 2022)
4.3 Date of Key Players Enter into Alpha-1 Lung Disease Market
4.4 Global Top Players Alpha-1 Lung Disease Headquarters and Area Served
4.5 Key Players Alpha-1 Lung Disease Product Solution and Service
4.6 Competitive Status
4.6.1 Alpha-1 Lung Disease Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Alpha-1 Lung Disease Products, Services and Solutions
5.1.4 Pfizer Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Baxter
5.2.1 Baxter Profile
5.2.2 Baxter Main Business
5.2.3 Baxter Alpha-1 Lung Disease Products, Services and Solutions
5.2.4 Baxter Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.2.5 Baxter Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Alpha-1 Lung Disease Products, Services and Solutions
5.3.4 AstraZeneca Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.3.5 Grifols Recent Developments
5.4 Grifols
5.4.1 Grifols Profile
5.4.2 Grifols Main Business
5.4.3 Grifols Alpha-1 Lung Disease Products, Services and Solutions
5.4.4 Grifols Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.4.5 Grifols Recent Developments
5.5 Teva Pharmaceutical Industries
5.5.1 Teva Pharmaceutical Industries Profile
5.5.2 Teva Pharmaceutical Industries Main Business
5.5.3 Teva Pharmaceutical Industries Alpha-1 Lung Disease Products, Services and Solutions
5.5.4 Teva Pharmaceutical Industries Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.5.5 Teva Pharmaceutical Industries Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Alpha-1 Lung Disease Products, Services and Solutions
5.6.4 Boehringer Ingelheim Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Kamada Ltd
5.7.1 Kamada Ltd Profile
5.7.2 Kamada Ltd Main Business
5.7.3 Kamada Ltd Alpha-1 Lung Disease Products, Services and Solutions
5.7.4 Kamada Ltd Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.7.5 Kamada Ltd Recent Developments
5.8 GlaxoSmithKline
5.8.1 GlaxoSmithKline Profile
5.8.2 GlaxoSmithKline Main Business
5.8.3 GlaxoSmithKline Alpha-1 Lung Disease Products, Services and Solutions
5.8.4 GlaxoSmithKline Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.8.5 GlaxoSmithKline Recent Developments
5.9 CSL Behring
5.9.1 CSL Behring Profile
5.9.2 CSL Behring Main Business
5.9.3 CSL Behring Alpha-1 Lung Disease Products, Services and Solutions
5.9.4 CSL Behring Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.9.5 CSL Behring Recent Developments
5.10 Takeda
5.10.1 Takeda Profile
5.10.2 Takeda Main Business
5.10.3 Takeda Alpha-1 Lung Disease Products, Services and Solutions
5.10.4 Takeda Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.10.5 Takeda Recent Developments
5.11 LFB Biomedicaments
5.11.1 LFB Biomedicaments Profile
5.11.2 LFB Biomedicaments Main Business
5.11.3 LFB Biomedicaments Alpha-1 Lung Disease Products, Services and Solutions
5.11.4 LFB Biomedicaments Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.11.5 LFB Biomedicaments Recent Developments
5.12 Abeona Therapeutics
5.12.1 Abeona Therapeutics Profile
5.12.2 Abeona Therapeutics Main Business
5.12.3 Abeona Therapeutics Alpha-1 Lung Disease Products, Services and Solutions
5.12.4 Abeona Therapeutics Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.12.5 Abeona Therapeutics Recent Developments
5.13 Biogen
5.13.1 Biogen Profile
5.13.2 Biogen Main Business
5.13.3 Biogen Alpha-1 Lung Disease Products, Services and Solutions
5.13.4 Biogen Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.13.5 Biogen Recent Developments
5.14 Vertex Pharmaceuticals
5.14.1 Vertex Pharmaceuticals Profile
5.14.2 Vertex Pharmaceuticals Main Business
5.14.3 Vertex Pharmaceuticals Alpha-1 Lung Disease Products, Services and Solutions
5.14.4 Vertex Pharmaceuticals Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.14.5 Vertex Pharmaceuticals Recent Developments
5.15 Baxalta
5.15.1 Baxalta Profile
5.15.2 Baxalta Main Business
5.15.3 Baxalta Alpha-1 Lung Disease Products, Services and Solutions
5.15.4 Baxalta Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.15.5 Baxalta Recent Developments
5.16 Arrowhead Research Corporation
5.16.1 Arrowhead Research Corporation Profile
5.16.2 Arrowhead Research Corporation Main Business
5.16.3 Arrowhead Research Corporation Alpha-1 Lung Disease Products, Services and Solutions
5.16.4 Arrowhead Research Corporation Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.16.5 Arrowhead Research Corporation Recent Developments
5.17 ProBioGen
5.17.1 ProBioGen Profile
5.17.2 ProBioGen Main Business
5.17.3 ProBioGen Alpha-1 Lung Disease Products, Services and Solutions
5.17.4 ProBioGen Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.17.5 ProBioGen Recent Developments
5.18 Chiesi Pharmaceuticals
5.18.1 Chiesi Pharmaceuticals Profile
5.18.2 Chiesi Pharmaceuticals Main Business
5.18.3 Chiesi Pharmaceuticals Alpha-1 Lung Disease Products, Services and Solutions
5.18.4 Chiesi Pharmaceuticals Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.18.5 Chiesi Pharmaceuticals Recent Developments
5.19 Kedrion Group
5.19.1 Kedrion Group Profile
5.19.2 Kedrion Group Main Business
5.19.3 Kedrion Group Alpha-1 Lung Disease Products, Services and Solutions
5.19.4 Kedrion Group Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.19.5 Kedrion Group Recent Developments
5.20 ProMetic Life Sciences
5.20.1 ProMetic Life Sciences Profile
5.20.2 ProMetic Life Sciences Main Business
5.20.3 ProMetic Life Sciences Alpha-1 Lung Disease Products, Services and Solutions
5.20.4 ProMetic Life Sciences Alpha-1 Lung Disease Revenue (US$ Million) & (2018-2023)
5.20.5 ProMetic Life Sciences Recent Developments
6 North America
6.1 North America Alpha-1 Lung Disease Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Alpha-1 Lung Disease Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alpha-1 Lung Disease Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alpha-1 Lung Disease Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alpha-1 Lung Disease Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alpha-1 Lung Disease Market Dynamics
11.1 Alpha-1 Lung Disease Industry Trends
11.2 Alpha-1 Lung Disease Market Drivers
11.3 Alpha-1 Lung Disease Market Challenges
11.4 Alpha-1 Lung Disease Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
